AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02420587|
Recruitment Status : Withdrawn
First Posted : April 20, 2015
Last Update Posted : April 20, 2015
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Drug: AMG 208 Behavioral: Questionnaire||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase 2 Study of AMG 208 Evaluating the Tumor Microenvironment in Metastatic Castration-Resistant Prostate Cancer|
|Study Start Date :||October 2014|
|Estimated Primary Completion Date :||October 2019|
Experimental: AMG 208
Dose of AMG 208 is 400 mg by mouth daily given in 6 weeks cycles. Participants receive AMG 208 until radiographic progression of disease and/or unequivocal clinical progression. Questionnaire completion about pain at baseline, Day 22 of Cycle 1, Day 1 of Cycle 2, Day 22 of Cycle 2, every 6 weeks, and at end of study visit.
Drug: AMG 208
Dose of AMG 208 is 400 mg by mouth daily given in 6 weeks cycles.
Questionnaire completion about pain at baseline, Day 22 of Cycle 1, Day 1 of Cycle 2, Day 22 of Cycle 2, every 6 weeks, and at end of study visit.
Other Name: Survey
- Progression-Free Survival (PFS) [ Time Frame: 6 weeks ]Progression free survival (PFS) defined as the time from treatment start to the time of clinical progression or death, whichever occurs first, or the time of last contact. The primary efficacy endpoint, PFS, continuously monitored using the Bayesian method by Thall et al.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02420587
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Amado Zurita, MD||M.D. Anderson Cancer Center|